Form D · Biotechnology
Leuko Labs, Inc.
Boston, MA · CIK 0001766291
Offering snapshot reported Feb 15, 2019 · SEC filing
- Reported sold
- $1.24M Offering amount: $1.74M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 1, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 15, 2019 | Initial | $1,244,974 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-333009
Source: Form D, filed Feb 15, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ian Butterworth | Director, Executive |
| Carlos Castro Gonzalez | Director, Executive |
| Paul Hartung | Director |
| Amy Salzhauer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8 St. Mary's Street #614
Boston, MA, 02215
Boston, MA, 02215